Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Edaravone Dexborneol Sequential Therapy in Acute Ischemic Stroke
NCT06176781Phase 3Not yet recruiting
- Sponsor
- Simcere Pharmaceutical Group
- Start
- Dec 2023
- Primary completion
- Mar 2025
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of edaravone dexborneol in ischemic stroke (2 arms), sponsored by Simcere Pharmaceutical Group. Primary endpoint: Proportion of subjects with modified Rankin scale score <= 1 at 90 days. Planned start Dec 2023; status: not yet recruiting.
02
Drugs
edaravone dexborneol
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT06176781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06176781.